PharmaCyte Biotech, Inc. (PMCB)
NASDAQ: PMCB · Real-Time Price · USD
1.740
-0.090 (-4.92%)
Nov 4, 2024, 4:00 PM EST - Market closed
PharmaCyte Biotech Balance Sheet
Financials in millions USD. Fiscal year is May - April.
Millions USD. Fiscal year is May - Apr.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jul '24 Jul 31, 2024 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 | Apr '21 Apr 30, 2021 | Apr '20 Apr 30, 2020 | 2019 - 2015 |
| Cash & Equivalents | 32.64 | 50.18 | 68.04 | 85.4 | 2.2 | 0.89 | Upgrade
|
| Cash & Short-Term Investments | 32.64 | 50.18 | 68.04 | 85.4 | 2.2 | 0.89 | Upgrade
|
| Cash Growth | -56.29% | -26.25% | -20.33% | 3778.14% | 146.08% | 73.67% | Upgrade
|
| Prepaid Expenses | 0.24 | 0.26 | 0.11 | 0.09 | 0.07 | 0.14 | Upgrade
|
| Total Current Assets | 32.88 | 50.44 | 68.15 | 85.49 | 2.28 | 1.04 | Upgrade
|
| Long-Term Investments | 29.12 | - | 1.57 | 1.57 | 1.57 | 1.57 | Upgrade
|
| Other Intangible Assets | 1.55 | 1.55 | 3.55 | 3.55 | 3.55 | 3.55 | Upgrade
|
| Other Long-Term Assets | 6.65 | 7.91 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Total Assets | 70.19 | 59.9 | 73.28 | 90.62 | 7.4 | 6.17 | Upgrade
|
| Accounts Payable | 0.55 | 0.39 | 0.13 | 0.21 | 0.17 | 0.19 | Upgrade
|
| Accrued Expenses | 0.68 | 0.74 | 0.46 | 0.5 | 0.5 | 0.7 | Upgrade
|
| Short-Term Debt | - | - | - | - | 0.05 | 0.11 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | - | - | - | 0.03 | Upgrade
|
| Other Current Liabilities | 6.23 | 0.46 | - | - | - | - | Upgrade
|
| Total Current Liabilities | 7.47 | 1.59 | 0.59 | 0.7 | 0.72 | 1.03 | Upgrade
|
| Long-Term Debt | - | - | - | - | - | 0.05 | Upgrade
|
| Other Long-Term Liabilities | 9.68 | 12.97 | - | - | - | - | Upgrade
|
| Total Liabilities | 17.15 | 14.56 | 0.59 | 0.7 | 0.72 | 1.08 | Upgrade
|
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 182.72 | 185.33 | 202.23 | 201.58 | 114.11 | 108.97 | Upgrade
|
| Retained Earnings | -92.2 | -115.63 | -115.96 | -111.65 | -107.41 | -103.86 | Upgrade
|
| Treasury Stock | -42.79 | -42.04 | -13.56 | - | - | - | Upgrade
|
| Comprehensive Income & Other | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 | Upgrade
|
| Total Common Equity | 47.71 | 27.65 | 72.69 | 89.92 | 6.68 | 5.09 | Upgrade
|
| Shareholders' Equity | 53.04 | 45.35 | 72.69 | 89.92 | 6.68 | 5.09 | Upgrade
|
| Total Liabilities & Equity | 70.19 | 59.9 | 73.28 | 90.62 | 7.4 | 6.17 | Upgrade
|
| Total Debt | - | - | - | - | 0.05 | 0.19 | Upgrade
|
| Net Cash (Debt) | 32.64 | 50.18 | 68.04 | 85.4 | 2.15 | 0.71 | Upgrade
|
| Net Cash Growth | -56.29% | -26.25% | -20.33% | 3869.72% | 204.54% | 37.10% | Upgrade
|
| Net Cash Per Share | 3.89 | 5.24 | 3.49 | 5.50 | 1.49 | 0.78 | Upgrade
|
| Filing Date Shares Outstanding | 7.68 | 7.71 | 8.78 | 20.75 | 1.61 | 1.56 | Upgrade
|
| Total Common Shares Outstanding | 7.72 | 8.04 | 16.79 | 20.72 | 1.59 | 1.09 | Upgrade
|
| Working Capital | 25.4 | 48.85 | 67.56 | 84.79 | 1.55 | 0.01 | Upgrade
|
| Book Value Per Share | 6.18 | 3.44 | 4.33 | 4.34 | 4.20 | 4.66 | Upgrade
|
| Tangible Book Value | 46.16 | 26.1 | 69.14 | 86.37 | 3.13 | 1.54 | Upgrade
|
| Tangible Book Value Per Share | 5.98 | 3.25 | 4.12 | 4.17 | 1.97 | 1.41 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.